Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN W CLINTON

Allopathic & Osteopathic Physicians Pediatrics

NPI
1740609601
CMS profile
3710775
Location
PORT LAVACA, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$24.62

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $24.62 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $12.93 1
Merck Sharp & Dohme Corporation $11.69 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN W CLINTON

NPI 1740609601 · CMS profile ID 3710775

Allopathic & Osteopathic Physicians / Pediatrics

PORT LAVACA, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740609601?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN W CLINTON, NPI 1740609601, CMS profile ID 3710775. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740609601?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JOHN W CLINTON, NPI 1740609601, CMS profile ID 3710775. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740609601?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JOHN W CLINTON, NPI 1740609601, CMS profile ID 3710775, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740609601?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $24.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $11.6904/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848691751 CMS
Novo Nordisk Inc $12.9303/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811724593 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $84.95 6
PY2020 $86.59 6
PY2021 $24.62 2
PY2022 $81.75 4
PY2023 $164.92 3
PY2024 $16.61 1
PY2025 $75.86 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $755,886.81 71
PY2024 Principal investigator $1,097,775.03 54
PY2023 Recipient $2,903.20 1
PY2023 Principal investigator $441,970.48 78
PY2022 Principal investigator $1,699,691.41 88
PY2021 Principal investigator $4,578,917.10 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $2,556.99 12/23/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963269309
Principal investigator 1 ModernaTX, Inc. $13,594.13 12/21/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963269303
Principal investigator 1 ModernaTX, Inc. $7,961.10 12/14/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963269297
Principal investigator 1 ModernaTX, Inc. $6,975.00 12/14/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963269315
Principal investigator 1 GlaxoSmithKline, LLC. $3,897.63 12/07/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945257
Principal investigator 1 ModernaTX, Inc. $5,000.00 12/07/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2, Two-Part Study (Open-Label [Part 1] Followed by ObserverBlind/Randomized [Part 2]) to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA1273.214 SARS-CoV-2 Vaccine in Participants Aged 12 Weeks to < 6 Months No dispute reported 06/30/2026 963269321
Principal investigator 1 ModernaTX, Inc. $903.64 12/01/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963269291
Principal investigator 1 GlaxoSmithKline, LLC. $3,085.83 11/23/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945243
Principal investigator 1 GlaxoSmithKline, LLC. $2,476.98 11/23/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945247
Principal investigator 1 ModernaTX, Inc. $5,600.25 11/23/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963678583
Principal investigator 1 ModernaTX, Inc. $14,608.60 11/23/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963678593
Principal investigator 1 ModernaTX, Inc. $409.60 11/23/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963678595
Principal investigator 1 ModernaTX, Inc. $5,525.58 11/16/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963678591
Principal investigator 1 ModernaTX, Inc. $5,600.25 11/14/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963678577
Principal investigator 1 ModernaTX, Inc. $5,600.25 11/14/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963678579
Principal investigator 1 ModernaTX, Inc. $5,600.25 11/14/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963678581
Principal investigator 1 ModernaTX, Inc. $24,673.00 11/14/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963678585
Principal investigator 1 ModernaTX, Inc. $83,915.26 11/14/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963678587
Principal investigator 1 ModernaTX, Inc. $205.34 11/14/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963678589
Principal investigator 1 ModernaTX, Inc. $8,826.91 10/28/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268679
Principal investigator 1 GlaxoSmithKline, LLC. $405.90 10/25/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945259
Principal investigator 1 ModernaTX, Inc. $41,741.05 10/19/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268675
Principal investigator 1 GlaxoSmithKline, LLC. $7,382.43 10/12/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945263
Principal investigator 1 ModernaTX, Inc. $28,792.01 10/12/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268669
Principal investigator 1 ModernaTX, Inc. $3,321.05 10/05/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268663
Principal investigator 1 GlaxoSmithKline, LLC. $1,483.02 10/03/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945235
Principal investigator 1 GlaxoSmithKline, LLC. $405.90 10/03/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945249
Principal investigator 1 ModernaTX, Inc. $225.00 09/28/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268373
Principal investigator 1 ModernaTX, Inc. $900.00 09/28/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268385
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/28/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268415
Principal investigator 1 ModernaTX, Inc. $1,775.71 09/28/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268421
Principal investigator 1 ModernaTX, Inc. $32,930.13 09/16/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268529
Principal investigator 1 GlaxoSmithKline, LLC. $4,403.52 09/14/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945239
Principal investigator 1 ModernaTX, Inc. $4,410.00 09/12/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268467
Principal investigator 1 ModernaTX, Inc. $5,902.99 09/12/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268473
Principal investigator 1 ModernaTX, Inc. $2,620.09 09/06/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268449
Principal investigator 1 GlaxoSmithKline, LLC. $405.90 09/01/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945231
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 09/01/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945245
Principal investigator 1 ModernaTX, Inc. $3,485.84 08/26/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268461
Principal investigator 1 ModernaTX, Inc. $1,929.59 08/24/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268431
Principal investigator 1 ModernaTX, Inc. $71,170.34 08/19/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268577
Principal investigator 1 GlaxoSmithKline, LLC. $405.90 08/17/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945237
Principal investigator 1 GlaxoSmithKline, LLC. $1,710.72 08/17/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945253
Principal investigator 1 GlaxoSmithKline, LLC. $3,421.44 08/17/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945255
Principal investigator 1 ModernaTX, Inc. $69,562.20 08/12/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268571
Principal investigator 1 ModernaTX, Inc. $10,503.58 08/03/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268491
Principal investigator 1 ModernaTX, Inc. $55,532.80 08/03/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268565
Principal investigator 1 GlaxoSmithKline, LLC. $2,522.52 08/01/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945229
Principal investigator 1 GlaxoSmithKline, LLC. $1,710.72 08/01/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945251
Principal investigator 1 ModernaTX, Inc. $1,103.36 07/27/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268409
Principal investigator 1 ModernaTX, Inc. $12,020.40 07/27/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268505
Principal investigator 1 ModernaTX, Inc. $50,946.03 07/27/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268553
Principal investigator 1 GlaxoSmithKline, LLC. $1,710.72 07/20/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945267
Principal investigator 1 ModernaTX, Inc. $11,323.71 07/15/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268605
Principal investigator 1 ModernaTX, Inc. $1,698.74 07/15/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268611
Principal investigator 1 ModernaTX, Inc. $17,887.20 07/15/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268617
Principal investigator 1 ModernaTX, Inc. $18,796.93 07/15/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268623
Principal investigator 1 ModernaTX, Inc. $21,004.67 07/15/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268629
Principal investigator 1 ModernaTX, Inc. $25,171.02 07/15/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268633
Principal investigator 1 ModernaTX, Inc. $29,656.44 07/15/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268639
Principal investigator 1 ModernaTX, Inc. $31,144.86 07/15/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268645
Principal investigator 1 GlaxoSmithKline, LLC. $1,185.03 07/06/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945241
Principal investigator 1 GlaxoSmithKline, LLC. $1,710.72 06/22/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945233
Principal investigator 1 ModernaTX, Inc. $5,922.56 06/17/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268479
Principal investigator 1 ModernaTX, Inc. $11,609.22 06/17/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268497
Principal investigator 1 ModernaTX, Inc. $95,057.53 06/17/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268583
Principal investigator 1 ModernaTX, Inc. $27,161.21 06/08/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268517
Principal investigator 1 ModernaTX, Inc. $1,086.45 06/03/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268403
Principal investigator 1 ModernaTX, Inc. $8,717.72 06/03/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268485
Principal investigator 1 ModernaTX, Inc. $41,345.30 06/03/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268547
Principal investigator 1 GlaxoSmithKline, LLC. $741.51 05/25/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945265
Principal investigator 1 ModernaTX, Inc. $953.60 05/25/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268391
Principal investigator 1 ModernaTX, Inc. $1,902.08 05/25/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268427
Principal investigator 1 GlaxoSmithKline, LLC. $202.95 05/11/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945261
Principal investigator 1 ModernaTX, Inc. $19,375.41 05/02/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268511
Principal investigator 1 ModernaTX, Inc. $29,395.87 05/02/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268523
Principal investigator 1 ModernaTX, Inc. $52,196.65 05/02/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268559
Principal investigator 1 ModernaTX, Inc. $184,887.90 05/02/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268595
Principal investigator 1 ModernaTX, Inc. $1,997.42 04/27/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268443
Principal investigator 1 ModernaTX, Inc. $3,229.48 04/27/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268455
Principal investigator 1 ModernaTX, Inc. $38,025.70 04/27/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268541
Principal investigator 1 GlaxoSmithKline, LLC. $1,710.72 04/21/2022 Non-covered Recipient Entity
ENSO MB LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 943945269
Principal investigator 1 ModernaTX, Inc. $371.20 04/20/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268379
Principal investigator 1 ModernaTX, Inc. $1,950.00 04/15/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268437
Principal investigator 1 ModernaTX, Inc. $1,000.00 03/30/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268397
Principal investigator 1 ModernaTX, Inc. $33,068.70 01/21/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268535
Principal investigator 1 ModernaTX, Inc. $97,968.51 01/21/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268589
Principal investigator 1 ModernaTX, Inc. $241,876.95 01/21/2022 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GRO
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963268601